APA (7th ed.) Citation

Cheng, Y., Wang, Q., Li, K., Shi, J., Liu, Y., Wu, L., . . . Li, X. (2021). Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: A randomised, double-blind, placebo-controlled Phase 2 study. British journal of cancer, 125(3), 366-371. https://doi.org/10.1038/s41416-021-01356-3

Chicago Style (17th ed.) Citation

Cheng, Ying, et al. "Anlotinib Vs Placebo as Third- or Further-line Treatment for Patients with Small Cell Lung Cancer: A Randomised, Double-blind, Placebo-controlled Phase 2 Study." British Journal of Cancer 125, no. 3 (2021): 366-371. https://doi.org/10.1038/s41416-021-01356-3.

MLA (9th ed.) Citation

Cheng, Ying, et al. "Anlotinib Vs Placebo as Third- or Further-line Treatment for Patients with Small Cell Lung Cancer: A Randomised, Double-blind, Placebo-controlled Phase 2 Study." British Journal of Cancer, vol. 125, no. 3, 2021, pp. 366-371, https://doi.org/10.1038/s41416-021-01356-3.